Anthem Biosciences IPO to Open on July 14, 2025: Check Latest GMP Today, Issue Size and Key Details
Anthem Biosciences is set to launch its IPO on July 14, 2025. The bidding window will be open for public subscription until July 16, 2025. The allotment process is expected to be finalised on Thursday, July 17, 2025. Anthem Biosciences IPO will be listed on BSE and NSE, with a tentative listing date fixed as Monday, July 21, 2025.
Anthem Biosciences IPO Details
Issue Size: ₹3,395 crores
Issue Type: 100% Offer for Sale (OFS) of 5.96 crore shares
Price Band: The issue price band is set at ₹540 - ₹570 per share
Lot Size: The minimum lot size of the issue is 26 shares
Minimum Investment: ₹14,040
Book-running Lead Managers: JM Financial Limited, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) Pvt Ltd (As per the RHP)
Registrar: Kfin Technologies Limited
Utilisation of Proceeds
The Company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Promoter Selling Shareholder after deduction of Offer related expenses and relevant taxes thereon, to be borne by the Promoter Selling Shareholder.
GMP Details
Ahead of its IPO, the Grey Market Premium (GMP) of Anthem Biosciences Limited stood at ₹79 as of July 9, 2025, 1:30 p.m. This indicates that the estimated listing price of the shares can be around ₹649, based on the upper end of the price band at ₹570. The expected gain per share is 13.86%.
|
Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Click here to check out newly Listed IPOs
About Anthem Biosciences Limited
Anthem Biosciences, founded in 2006 and headquartered in Bengaluru, is a leading Indian Contract Research, Development & Manufacturing Organization (CRDMO). It offers end-to-end services across drug discovery, development, and manufacturing for both small molecules and biologics. The company serves over 550 clients across 44 countries, with major contributions from regulated markets like the US, Europe, and Japan.
In FY25, Anthem Biosciences reported a revenue of ₹1,844.6 crore and a net profit of ₹451.3 crore.
|
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. To read the RA disclaimer, please click here |